What Are the Current Challenges in KRAS Inhibitor Development?
Several challenges hinder the development and clinical application of KRAS inhibitors: - Drug Resistance: Cancer cells can develop resistance to KRAS inhibitors, reducing their effectiveness over time. - Toxicity: Targeting the KRAS pathway can sometimes affect normal cells, leading to adverse side effects. - Specificity: Achieving high specificity to target only the mutant KRAS without affecting the wild-type protein is challenging.
